Search | Clinical Trials Finder

Conditions: Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
Interventions: TAS6417; Drug
Lead sponsor: Taiho Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 9
States / cities: Henderson, Nevada • Las Vegas, Nevada • Canton, Ohio + 1 more

Conditions: Sickle Cell Disease, Sickle Cell Anemia, Sickle Cell Disorders, Hemoglobin S Disease, Sickling Disorder Due to Hemoglobin S
Interventions: HQK-1001; Drug
Lead sponsor: HemaQuest Pharmaceuticals Inc.; Industry
Eligibility: 12 Years to 60 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 9
States / cities: Oakland, California • Miami, Florida • Augusta, Georgia + 6 more

Conditions: Infection, Human Immunodeficiency Virus I
Interventions: LEXIVA (GW433908), Ritonavir; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2013
U.S. locations: 16
States / cities: Birmingham, Alabama • Los Angeles, California • Oakland, California + 10 more

Conditions: Lymphoma, Non-Hodgkin, Relapsed Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Lymphoma, B Cell Lymphoma, B-Cell Non-Hodgkin's Lymphoma, Hematologic Malignancy, Relapsed/Refractory Multiple Myeloma, Relapsed/Refractory Acute Myeloid Leukemia
Interventions: Caribou-sponsored investigational therapy; Biological
Lead sponsor: Caribou Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2041
U.S. locations: 31
States / cities: Birmingham, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 25 more

Conditions: Pancreatic Ductal Adenocarcinoma (PDAC), Family History of Pancreas Cancer, Genetic Testing, Multi-cancer Early Detection
Interventions: Telephone education session, Online educational materials; Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: LPL Deficiency
Interventions: alipogene tiparvovec, Prednisolone, Cyclosporins, Mycophenolate mofetil; Drug
Lead sponsor: UniQure Biopharma B.V.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Down Syndrome (DS), Keratoconus, Pellucid Marginal Degeneration, Forme Fruste Keratoconus (FFK)
Interventions: Epi-ON corneal cross-linking (CXL); Combination Product
Lead sponsor: Woolfson Eye Institute; Other
Eligibility: 8 Years and older
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 12
States / cities: Atlanta, Georgia • Canton, Georgia • Cumming, Georgia + 8 more

Conditions: Multiple Myeloma
Interventions: Pembrolizumab, Daratumumab; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 3
States / cities: Jacksonville, Florida • Atlanta, Georgia • Bloomfield Hills, Michigan

Conditions: High-risk Smoldering Multiple Myeloma, Smoldering Multiple Myeloma, Multiple Myeloma
Interventions: Teclistamab, Lenalidomide, Dexamethasone; Drug
Lead sponsor: Irene Ghobrial, MD; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 3
States / cities: Denver, Colorado • Boston, Massachusetts • Portland, Oregon

Conditions: Duchenne Muscular Dystrophy
Interventions: NS-050/NCNP-03, Placebo; Drug
Lead sponsor: NS Pharma, Inc.; Industry
Eligibility: 4 Years to 15 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 6
States / cities: Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 3 more

Conditions: Trauma, Rib Fractures, Chest Wall Disorder, Respiratory Insufficiency, Pain, Chest, Rib Trauma, Rib Fracture Multiple, Respiratory Failure, Respiratory Distress Syndrome
Interventions: Percutaneous Cryoablation of Intercostal Nerves, Multi-modal pain regimen; Procedure · Other
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Multiple Myeloma
Interventions: Denileukin Diftitox (Ontak); Drug
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years to 70 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Retinitis Pigmentosa
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: Not listed
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions: VX-407, Placebo, Midazolam; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 159 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Allergic Rhinitis
Interventions: NVP-VAK694; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: North Miami Beach, Florida

Conditions: Acute Lymphoblastic Leukemia (ALL)
Interventions: Sedentary time intervention; Behavioral
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 12 Years to 21 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Cutaneous Skeletal Hypophosphatemia Syndrome (CSHS), Epidermal Nevus Syndrome
Interventions: Burosumab; Drug
Lead sponsor: Laura Tosi; Other
Eligibility: Not listed
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Multiple Sclerosis
Interventions: Amygdala insula retraining, Lifestyle program; Behavioral
Lead sponsor: Chronic Conditions Research Fund; Other
Eligibility: 21 Years to 65 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Decorah, Iowa

Conditions: Multiple Myeloma
Interventions: bendamustine, bortezomib; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 13
States / cities: Encinitas, California • Roseville, California • San Diego, California + 10 more

Conditions: Pancreatic Neuroendocrine Tumor, Pancreas Cancer
Interventions: cytoreductive surgery, Lutathera - a small molecule used in Peptide Receptor Radionuclide Therapy (PRRT), Peptide receptor radionuclide therapy (PRRT); Procedure · Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Essential Tremor
Interventions: Sodium Oxybate, Placebo; Drug · Other
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 50 Years to 75 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Bingham Farms, Michigan

Conditions: Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions: Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR), Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 8
States / cities: Little Rock, Arkansas • Bradenton, Florida • South Miami, Florida + 4 more

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nonmalignant Neoplasm
Interventions: trivalent influenza vaccine, Immunoenzyme technique, Laboratory biomarker analysis; Biological · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 459 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2013
U.S. locations: 2
States / cities: Duarte, California • Pasadena, California

Conditions: Traumatic Brain Injury, Posttraumatic Stress Disorders, Trauma, Combat Disorders, Pain
Interventions: TMRDU; Device
Lead sponsor: University of Illinois at Chicago; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 3
States / cities: Camp Pendleton, California • Tampa, Florida • Fort Knox, Kentucky

Search by objective public record fields.

REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)

A Study of HQK-1001 in Patients With Sickle Cell Disease

48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pediatric Patients With HIV Infection

Long-Term Follow-up Study

Reach and Engagement of GENetic Education, Risk Assessment, and TEsting Feasibility Trial

Alipogene Tiparvovec for the Treatment of LPLD Patients

Compassionate Use Study of Epi-ON Corneal Collagen Crosslinking Performed Using UVA Exposure on Eyes With Ectatic Corneal Diseases for Subjects With Down Syndrome

Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668)

Immuno-PRISM (PRecision Intervention Smoldering Myeloma)

NS-050/NCNP-03 in Boys With DMD (Meteor50)

Percutaneous Cryoablation of Intercostal Nerves for the Treatment of Rib Fractures

Dose Escalation Trial of Denileukin Diftitox (Ontak) Post Autologous Transplantation

Study of Usher Syndromes, Type 1 and Type 2

A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants

Safety and Tolerability of Single and Multiple Doses of VAK694 in Healthy and Atopic Subjects

Reduce Sedentary Time in Acute Lymphoblastic Leukemia

Burosumab for CSHS

Amygdala Insula Retraining in the Management of Multiple Sclerosis Symptoms

Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma

Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver

Multiple-dose,Double-blind,Placebo-controlled Study of Sodium Oxybate in Patients With Essential Tremor

Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.

Flu Vaccine in Preventing Influenza Infection in Healthy Volunteers and in Patients Who Have Undergone Stem Cell Transplant

Telepharmacy Robotic Medicine Delivery Unit "TRMDU" Assessment